If you’ve recently taken Wegovy/Mounjaro, etc, or still are, it’s completely normal to wonder whether a weight loss clinical trial is still an option.
A lot of people assume trials are only for “brand new” starters. In reality, many volunteers come to research with some history: previous diets, previous programmes, other medications, and sometimes previous or current GLP-1 treatment. The key is that a clinical trial must protect your safety and clearly answer a research question, which means the study team needs a good understanding of what your “starting point” looks like.
The honest answer: sometimes, but it depends on the study design
Some obesity clinical trials will accept people who are currently using a GLP-1 medication. Others won’t. Some may accept you, but only if your dose has been stable for a certain period. Others may require a “washout” period (a gap after stopping treatment) before screening.
That isn’t the study team being difficult. It’s because Wegovy is designed to have a long duration of action (as reflected in its prescribing information, it has a long half-life). If a study is trying to measure the effect of a trial treatment, it needs to minimise anything that could blur the results. This includes the lingering effects of another medication.
Why trials might require a stable dose or a washout period
Think of it like testing a new pair of glasses. If you’re already wearing a prescription lens underneath, it becomes hard to know what’s helping. In weight-loss research, the same principle applies. A study may ask for stability or a washout period so that:
1) The trial can make fair comparisons. If one participant still has an active medication effect in their system and another doesn’t, outcomes can look “better” or “worse” for reasons that aren’t actually related to the study treatment.
2) Safety monitoring stays clear. Trials need to be able to interpret symptoms and side effects appropriately. If two treatments overlap, it can be harder to tell what’s causing what, and that matters for your care and the study’s safety reporting.
3) Eligibility criteria are applied consistently. Trials have protocols for a reason. In properly regulated UK clinical research, the protocol is reviewed and monitored, and participant safety is the priority throughout.
Don’t stop medication just to “fit” a trial
It’s worth stating plainly that you shouldn’t discontinue Wegovy (or any prescribed medication) purely to try to qualify for a study. Decisions about stopping, switching, or pausing treatment should always be made with a qualified clinician who understands your health history.
A good trial team will never pressure you into changing treatment just to join. They’ll explain what the study needs, why it needs it, and what your options are.
Approach the study team instead
If you’re in this position and are now considering what to do next, we recommended engaging a study team and sharing your timeline. In practical terms, that means being ready to share:
- when you started Wegovy/Mounjaro (or similar)
- your current dose and whether it has changed recently
- when your last injection was
- whether you’ve had side effects that led to dose changes or stopping
- any other medications (especially those affecting blood sugar, appetite, or gastrointestinal symptoms)
It’s never about judgement. It’s about safety and clarity. Most eligibility decisions become much easier once the study team can see the full picture.
Common scenarios
1) “I’m on Wegovy right now and it’s going well.”You may still be eligible for some obesity clinical trials, but the study may require a stable dose for a set period before screening. That’s because rapid dose changes can affect appetite, weight trajectory, and side effects. All of which can interfere with what the trial is measuring.
2) “I stopped recently, can I join now?”Possibly, but some studies will ask for a gap between your last dose and screening. With long-acting medications, that gap can be important for safety interpretation and for reliably measuring baseline outcomes.
3) “I’m switching treatments and I’m not sure what I’m ‘on’ anymore.”This is exactly the kind of situation the study team needs to know about early. Switching can affect symptoms, hunger, energy levels, and weight patterns. This may influence whether a trial can safely include you at that moment.
How a regulated UK trial makes these decisions (and what you’re entitled to)
If a study is properly regulated, you should be given clear information you can understand, not vague reassurance. You should expect an explanation of what the trial is trying to learn, what participation involves, and what your rights are as a volunteer (including the right to decline or withdraw). In the UK, research ethics review exists specifically to protect participants and ensure studies are designed and conducted appropriately.
At Panthera, the volunteer experience is positioned around support and safety, with research delivered through established clinical sites and structured processes.
The best questions to ask upfront (without feeling awkward)
If you want to make a quick decision, especially if you’re busy or anxious about the best approach, then you should focus on questions that give you practical clarity.
Start with whether the trial allows current or recent GLP-1 use, and if so, what “stable” means in that specific protocol. Then ask what the screening process involves, how long the screening visit typically takes, and whether there are any critical timing requirements around medication history. Finally, ask how the team handles safety concerns between visits and what support routes exist if symptoms change.
If the study is a good fit, those questions won’t be treated as difficult. They’ll be treated as normal.
A simple next step (without changing anything first)
If you’re currently on treatment, or you’ve recently stopped, the safest move is not to make changes alone just to “fit” a trial. Instead, bring your medication timeline to a study team and let them tell you what’s possible, what would need to be stable, and what would make participation unsafe or impractical right now.
If you’d like to explore options, register your interest or contact Panthera via the Contact & Support route. Even a short initial conversation can clarify whether a study might suit your situation, and if not, what might be more realistic next.
